{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:12:10Z","timestamp":1772115130345,"version":"3.50.1"},"reference-count":40,"publisher":"Gobierno de Navarra","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An Sist Sanit Navar"],"DOI":"10.23938\/assn.1017","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T11:51:01Z","timestamp":1682509861000},"source":"Crossref","is-referenced-by-count":2,"title":["Corticoid treatment and SARS-CoV-2 variants: two independent factors associated with COVID-19 mortality in a Spanish regional hospital"],"prefix":"10.23938","volume":"46","author":[{"given":"Juan","family":"Salas Jarque","sequence":"first","affiliation":[{"name":"Facultad de Medicina. Universidad de Zaragoza. Zaragoza. Espa\u00f1a. jsjarque@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Moreno D\u00edaz","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n M\u00e9dica. Hospital Royo Villanova. Zaragoza. Espa\u00f1a.. javimorenomdr@hotmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bustos Morell","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia. Hospital de Barbastro. Barbastro. Espa\u00f1a.. cbustos@salud.aragon.es"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Pereira Boan","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda. Hospital de Barbastro. Barbastro. Espa\u00f1a.. jpereiraboan@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Dur\u00e1n Portella","sequence":"additional","affiliation":[{"name":"Servicio de Admisi\u00f3n y Documentaci\u00f3n. Hospital de Barbastro. Barbastro. Espa\u00f1a.. aduran@salud.aragon.es"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Ruiz Montes","sequence":"additional","affiliation":[{"name":"Servicio de Admisi\u00f3n y Documentaci\u00f3n. Hospital de Barbastro. Barbastro. Espa\u00f1a.. fruiz@salud.aragon.es"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Velilla Marco","sequence":"additional","affiliation":[{"name":"Facultad de Medicina. Universidad de Zaragoza. Zaragoza. Espa\u00f1a.. jvelillam@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10024","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. WU C, CHEN X, CAI Y, XIA J, ZHOU X, XU S et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180(7): 934-943. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. TUFAN ZK, KAYAASLAN B, MER M. COVID-19 and sepsis. Turk J Med Sci 2021; 51(SI-1): 3301-3311. https:\/\/doi.org\/10.3906\/sag-2108-239.","DOI":"10.3906\/sag-2108-239"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. ZHOU F, YU T, DU R, FAN G, LIU Y, LIU Z et al. Clinical course and risk factors and mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-1062. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"ref3","unstructured":"4. Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. Consultado el 1 de marzo de 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html"},{"key":"ref4","unstructured":"5. Centers for Disease Control and Prevention. Science brief: Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19 Consultado el 1 de marzo de 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlying-evidence-table.html"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. TAHIRA AC, VERJOVSKI-ALMEIDA S, FERREIRA ST. Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients. Alzheimers Dement 2021; 17(11): 1818-1831. https:\/\/doi.org\/10.1002\/alz.12352","DOI":"10.1002\/alz.12352"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. OZTURK S, TURGUTALP K, ARICI M, ODABAS AR, ALTIPARMAK MR, AYDIN Z et al. Mortality analysis of COVID-19 infection in chronic kidney disease in haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transplant 2020; 35(12): 2083-2095. https:\/\/doi.org\/10.1093\/ndt\/gfaa271","DOI":"10.1093\/ndt\/gfaa271"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. HOLMAN N, KNIGHTON P, KAR P, O'KEEFE J, CURLEY M, WEAVER A et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 2020; 8(10): 823-833. https:\/\/doi.org\/10.1016\/S2213-8587(20)30271-0","DOI":"10.1016\/S2213-8587(20)30271-0"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. \u00c1LVAREZ-GARC\u00cdA, J, LEE S, GUPTA A, CAGLIOSTRO M, JOSHI AA, RIVAS-LASARTE M et al. Prognostic impact of prior heart failure in patients hospitalized with COVID-19. J Am Coll Cardiol 2020; 76(20): 2334-2348. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.549","DOI":"10.1016\/j.jacc.2020.09.549"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. PABLOS JL, GALINDO M, CARMONA L, LLED\u00d3 A, RETUERTO M, BLANCO R et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020; 79(12): 1544-1549. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218296","DOI":"10.1136\/annrheumdis-2020-218296"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. ZHOU Y, CHI J, LV W, WANG Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19). Diabetes Metab Res Rev 2021; 37(2): e3377. https:\/\/doi.org\/10.1002\/dmrr.3377","DOI":"10.1002\/dmrr.3377"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. HASHEMI N, VIVEIROS K, REDD WD, ZHOU JC, MCCARTHY TR, BAZARBASHI AN et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicenter United States experience. Liver Int 2020; 40(10): 2515-2521. https:\/\/doi.org\/10.1111\/liv.14583","DOI":"10.1111\/liv.14583"},{"key":"ref12","unstructured":"13. National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Consultado el 15 de junio de 2022. https:\/\/www.COVID19treatmentguidelines.nih.gov"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. L\u00d3PEZ-BERNAL J, ANDREWS N, GOWER C., ROBERTSON C, STOWE J, TESSIER E et al. Effectiveness of the Pfizer-BioNTech and Oxford AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021; 373: n1088. https:\/\/doi.org\/10.1136\/bmj.n1088","DOI":"10.1136\/bmj.n1088"},{"key":"ref14","unstructured":"15. Ministerio de Sanidad. Actualizaci\u00f3n n\u00ba 531. Enfermedad por el coronavirus (COVID-19). 28 de diciembre de 2021. https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/12\/Actualizacion_531_COVID-19.pdf"},{"key":"ref15","unstructured":"16. Transparencia Arag\u00f3n. COVID-19. Situaci\u00f3n actual. Consultado el 30 de abril de 2022. Disponible en https:\/\/transparencia.aragon.es\/COVID19\/"},{"key":"ref16","unstructured":"17. Servicio Aragon\u00e9s de Salud. Sector Sanitario de Barbastro. El Sector. Consultado el 14 de junio de 2022. http:\/\/sectorbarbastro.salud.aragon.es\/index.php\/es\/elsector"},{"key":"ref17","unstructured":"18. LORENZO TEMPRANO L. El SARS-COVID-19. Evoluci\u00f3n en la codificaci\u00f3n con CIE-10-ES 10\u00aa edici\u00f3n - enero 2020, actualizaciones y revisiones posteriores hasta el a\u00f1o 2021. Nuevo Hospital 2022; XVIII(1): 2-8. https:\/\/www.saludcastillayleon.es\/CAZamora\/es\/publicaciones\/revista-nuevo-hospital-2022\/nuevo-hospital-2022-febrero-xviii-1\/lorenzo-temprano-l-sars-covid19-evolucion-codificacion-cie.ficheros\/2104264-NUEVOHOSPITAL,2022febrero;XVIII(1)2-8.pdf"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. COLSON P, LEVASSEUR A, GAUTRET P, FENOLLAR F, HOANG VT, DELERCE J et al. Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa: an investigational study. Travel Med Infect Dis 2021; 40: 101980. https:\/\/doi.org\/10.1016\/j.tmaid.2021.101980","DOI":"10.1016\/j.tmaid.2021.101980"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. FOURNIER PE, COLSON P, LEVASSEUR A, DEVAUX CA, GAUTRET P, BEDOTTO M et al. Emergence and outcomes of the SARS-CoV-2 \"Marseille-4\" variant. Int J Infect Dis 2021; 106: 228-236. https:\/\/doi.org\/10.1016\/j.ijid.2021.03.068","DOI":"10.1016\/j.ijid.2021.03.068"},{"key":"ref20","unstructured":"21. CoVariants. Overview of variants in countries [Internet]. Consultado el 10 de agosto de 2022. https:\/\/covariants.org\/per-country?country=Spain"},{"key":"ref21","unstructured":"22. GARC\u00cdA MAR\u00cdN AM, CHINER OMS A, GONZ\u00c1LEZ CANDELAS F, COMAS ESPADAS I, L\u00d3PEZ MG, COSCOLLA DEVIS M. Lo que nos ense\u00f1a la epidemiolog\u00eda gen\u00f3mica sobre las olas de COVID-19 en Espa\u00f1a (y c\u00f3mo evitar una nueva ola). 11.07.2021. Consultado el 15 de junio 2022. https:\/\/theconversation.com\/lo-que-nos-ensena-la-epidemiologia-genomica-sobre-las-olas-de-COVID-19-en-espana-y-como-evitar-una-nueva-ola-155401"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. GAMERO DE LUNA EJ, GAMERO EST\u00c9VEZ E. Mutaciones, variantes y cepas de SARS-CoV-2. Semergen 2021; 47(3): 208-209. https\/\/doi.org\/10.1016\/j.semerg.2021.01.001","DOI":"10.1016\/j.semerg.2021.01.001"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. MENDIOLA-PASTRANA IR, L\u00d3PEZ-ORTIZ E, R\u00cdO DE LA LOZA-ZAMORA JG, GONZ\u00c1LEZ J, G\u00d3MEZ-GARC\u00cdA, A, L\u00d3PEZ-ORTIZ G. SARS-CoV-2 variants and clinical outcomes: a systematic review. Life (Basel) 2022; 12(2): 170. https:\/\/doi.org\/10.3390\/life12020170","DOI":"10.3390\/life12020170"},{"key":"ref24","unstructured":"25. Ministerio de Sanidad. Actualizaci\u00f3n de la situaci\u00f3n epidemiol\u00f3gica de las variantes de SARS-CoV-2 en Espa\u00f1a a 27 de junio de 2022. Consultado el 30 de junio de 2022. https:\/\/www.sanidad.gob.es\/profesionales\/saludPublica\/ccayes\/alertasActual\/nCov\/documentos\/COVID19_Actualizacion_variantes_20220627.pdf"},{"key":"ref25","unstructured":"26. Situaci\u00f3n de COVID-19 en Espa\u00f1a a 29 de diciembre de 2021. Equipo COVID-19. Red Nacional de Vigilancia Epidemiol\u00f3gica. Centro Nacional de Epidemiolog\u00eda. CNM (Instituto de Salud Carlos III). Consultado el 30 de junio de 2022. https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Paginas\/InformesCOVID-19.aspx"},{"key":"ref26","unstructured":"27. GEDDES L. From Alpha to Omicron: everything you need to know about SARS-CoV-2 variants of concern. Consultado el 30 de junio de 2022. https:\/\/www.gavi.org\/vaccineswork\/alpha-omicron-everything-you-need-know-about-coronavirus-variants-concern"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. ZAREI J, BADAVI M, KARANDISH M, SHOUSHTARI MH, DASTOORPOOR M, YOUSEFI F et al. A study to design minimum data set of COVID-19 registry system. BMC Infect Dis 2021; 21(1): 773. https:\/\/doi.org\/10.1186\/s12879-021-06507-8","DOI":"10.1186\/s12879-021-06507-8"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. CASAS-ROJO J, ANT\u00d3N-SANTOS J, MILL\u00c1N-N\u00da\u00d1EZ-CORT\u00c9S J, LUMBRERAS-BERMEJO C, CASAS-ROJO JM, ROY-VALLEJO E et al. Caracter\u00edsticas cl\u00ednicas de los pacientes hospitalizados con COVID-19 en Espa\u00f1a: resultados del Registro SEMI-COVID-19. Rev Clin Esp (Barc) 2020; 220(8): 480-494. https:\/\/doi.org\/ 10.1016\/j.rce.2020.07.003","DOI":"10.1016\/j.rce.2020.07.003"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. G\u00d3MEZ ANT\u00daNEZ M, MUI\u00d1O M\u00cdGUEZ A, BENDALA ESTRADA A, MAESTRO DE LA CALLE G, MONGE MONGE, D, BOIXEDA R et al. Clinical characteristics and prognosis of COPD patients hospitalized with SARS-CoV-2. Int J Chron Obstruct Pulmon Dis 2021; 15: 3433-3445. https\/\/doi.org\/10.2147\/COPD.S276692","DOI":"10.2147\/COPD.S276692"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. KUSWARDHANI RAT, HENRINA J, PRANATA R, LIM MA, LAWRENSIA S, SUASTIKA K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr 2020; 14(6): 2103-2109. https:\/\/doi.org\/10.1016\/j.dsx.2020.10.022","DOI":"10.1016\/j.dsx.2020.10.022"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. HASHIM MJ, ALSUWAIDI AR, KHAN G. Population risk factors por COVID-19 mortality in 93 countries. J Epidemiol Glob Health 2020; 10(3): 204-208. https:\/\/doi.org\/10.2991\/jegh.k.200721.001","DOI":"10.2991\/jegh.k.200721.001"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. BOOTH A, REED AB, PONZO S, YASSAEE A, ARAL M, PLANS D et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One 2021; 16(3): e0247461. https:\/\/doi.org\/10.1371\/journal.pone.0247461","DOI":"10.1371\/journal.pone.0247461"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. BOIXEDA R, CAMPINS L, JUANOLA J, FORCE L, en nombre del grupo COCOHMAT (Cohorte COVID del Hospital de MATar\u00f3). \u00bfEs la enfermedad pulmonar obstructiva cr\u00f3nica un factor protector en la infecci\u00f3n por SARS-CoV-2? La importancia del tratamiento broncodilatador. Rev Clin Esp (Barc) 2020; 220(8): 526-529. https:\/\/doi.org\/10.1016\/j.rce.2020.07.001","DOI":"10.1016\/j.rce.2020.07.001"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. WIERSINGA WJ, RHODES A, CHENG AC, PEACOCK SJ, PRESCOTT HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus: a review. JAMA 2020; 324(8): 782-793. https:\/\/doi.org\/10.1001\/jama.2020.12839","DOI":"10.1001\/jama.2020.12839"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384(8): 693-704. https:\/\/doi.org\/ 10.1056\/NEJMoa2021436","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. VAN DEN EYNE E, GASCH O, OLIVA JC, PRIETO E, CALZADO S, GOMILA A et al. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. Infect Dis (Lond) 2021; 53(4): 291-302. https:\/\/doi.org\/ 10.1080\/23744235.2021.1884286","DOI":"10.1080\/23744235.2021.1884286"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. VISWANATHA GL, ANJANA MALE CH KVLSN, SHYLAJA H. Efficacy and safety of tocilizumab in the management of COVID-19: a systematic review and meta-analysis of observational studies. Clin Exp Rheumatol 2022; 40(3): 634-646. https:\/\/doi.org\/ 10.55563\/clinexprheumatol\/4dg0or","DOI":"10.55563\/clinexprheumatol\/4dg0or"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. BEIGEL JH, TOMASHEK, DODD LE, META AK, ZINGMAN BS, KALIL AC et al. Remdesivir for the treatment of COVID-19 - Final report. N Engl J Med 2020; 383(19): 1813-1826. https:\/\/doi.org\/10.1056\/NEJMoa2007764","DOI":"10.1056\/NEJMoa2007764"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. AOMAR-MILL\u00c1N IF, SALVATIERRA J, TORRES-PAREJO U, FARO-MIGUEZ N, CALLEJAS-RUBIO JL, CEBALLOS-TORRES A et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. Intern Emerg Med 2021; 16(4): 843-852. https:\/\/doi.org\/10.1007\/s11739-020-02600-z","DOI":"10.1007\/s11739-020-02600-z"}],"container-title":["Anales del Sistema Sanitario de Navarra"],"original-title":[],"link":[{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/95536\/72567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:05:16Z","timestamp":1747307116000},"score":1,"resource":{"primary":{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/95536\/72567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,4,25]]}},"URL":"https:\/\/doi.org\/10.23938\/assn.1017","relation":{},"ISSN":["2340-3527"],"issn-type":[{"value":"2340-3527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"article-number":"e1017"}}